Phibro Animal Health's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Phibro Animal Health's ROA in the fourth quarter of 2026?
Phibro Animal Health Corporation achieved a return on average assets (ROA) of 6.7 % in its fourth quarter of 2026, which is below Phibro Animal Health's average return on assets, which stands at 6.89%.

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 127 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 915, from total ROA ranking in the third quarter of 2026 at 1064.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	28.87 %	9.71 %	38.56 %	43.39 %	39.02 %
Y / Y Net Income Change	26.05 %	15.06 %	762.14 %	280.32 %	2190.43 %
Net Income (TTM) in million	100	95	92	68	48
Return On Assets (TTM)	6.7 %	6.85 %	6.78 %	5.37 %	4.17 %
PAHC's Total Ranking	# 915	# 1064	# 1129	# 1329	# 1585
Total Assets (TTM) in million	1,761	1,445	1,361	1,386	1,367
Seq. Total Assets Change	21.88 %	6.19 %	-1.78 %	1.37 %	3.76 %
Seq. Net Income Change	-9.63 %	-12.51 %	3.51 %	54.01 %	-17.51 %

PAHC's 5 Years Annual ROA >> Back to PAHC Management Effectiveness >> Compare PAHC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 49
Sector	# 128
Overall	# 890

Return On Assets Statistics
High	Average	Low
15.13 %	6.89 %	0.25 %
(Jun 30 2016)		(Jun 30 2024)

Financial Statements
Phibro Animal Health's Assets	$ 1,761 million	PAHC's Balance sheet
Phibro Animal Health's Income	$ 22 million	Quarterly PAHC's Income Statement
PAHC's Income by Division		See PAHC's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	29.43 %	38.56 %	1.11 %	4.26 %	10.74 %
Total Assets in million	1,761	1,361	982	971	932
Y / Y Net Income Change	106.61 %	1897.68 %	-92.59 %	-33.69 %	-9.58 %
Net Income in million	100	48	2	33	49
Annual Return On Assets	5.66 %	3.55 %	0.25 %	3.36 %	5.28 %

PAHC's 5 Years Annual ROA >> Back to PAHC Management Effectiveness >> Compare PAHC ROA to its Competitors

Comment on PAHC's ROA in the fiscal year ending 2026

In the fiscal year 2026 ROA improved to 5.66 % compared to prior year, due to annual net income growth of 106.61 % to $99.72 million, while value of Phibro Animal Health's overall assets grew just by 29.43 % to $1,761.36 million, compared to $1,761.36 a year before.

More Return On Assets Ratios
PAHC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PAHC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PAHC's Competitors
Subscribers only: Roa for Phibro Animal Health's Suppliers
Subscribers only: Return On Assets for PAHC's Customers

You may also want to know
PAHC's Roi	PAHC's Inventory Turnover Ratio	PAHC's Growth Rates	PAHC's Dividend Comparisons
	PAHC's Profitability Ratios	PAHC's Asset Turnover Ratio	PAHC's Dividend Growth
PAHC's Roe	PAHC's Valuation Ratios	PAHC's Financial Strength Ratios	PAHC's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %
Illumina Inc	12.68 %
Spero Therapeutics Inc	12.57 %
Transmedics Group Inc	12.50 %
Eton Pharmaceuticals Inc	12.37 %
Nephros Inc	12.30 %
Msa Safety Inc	12.23 %

Date modified: 2026-09-08T15:22:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.